IP Library › Granted Patent US 11,673,908
Granted Patent B2
US 11,673,908 · App. 17/878,650 · Granted Jun 13, 2023

Utility of nematode small molecules

Inventors: Andrea Choe (Pasadena, CA); Paul W. Sternberg (San Marino, CA); Frank C. Schroeder (Ithaca, NY); Stephan H. Von Reuss (Jena, DE)
Assignees: California Institute of Technology; Boyce Thompson Institute for Plant Research
C07H15/04A01N37/36A01N43/16A01N43/38A61K31/454A61K31/7028C07H15/08C07H15/10C07H15/18C07H15/26C07D309/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,673,908
App. No.
17/878,650
Granted
Jun 13, 2023
Kind
B2
Abstract

The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.

Claims (11)

1. A pharmaceutical composition comprising ascr #7 and a sugar, a nucleobase, a fatty acid, and/or an amino acid, in a dosage form formulated for alleviating an inflammatory or immune disorder.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition consists of the ascr #7 and a sugar.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition consists of the ascr #7, a sugar, and a nucleobase.

4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition consists of the ascr #7, a sugar, and a fatty acid.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition consists of the ascr #7, a sugar, and an amino acid.

6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition consists of the ascr #7, a sugar, a nucleobase, a fatty acid, and an amino acid.

7. The pharmaceutical composition of claim 1 , wherein the inflammatory or immune disorder is asthma.

8. A pharmaceutical composition consisting of ascr #7 and a sugar, a nucleobase, a fatty acid, and/or an amino acid, in a dosage form formulated for alleviating an inflammatory or immune disorder.

9. A method of alleviating an inflammatory or immune disorder in a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition of claim 8 .

10. The method of claim 9 , wherein the pharmaceutical composition is administered orally.

11. The method of claim 9 , wherein the inflammatory or immune disorder is asthma.

Assignments (4)
CONFIRMATORY LICENSE Recorded Aug 2, 2023
From: BOYCE THOMPSON INST FOR PLANT RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064476/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2023
From: CHOE, ANDREA; STERNBERG, PAUL WARREN
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 062857/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2023
From: VON REUSS, STEPHAN HEINRICH
To: BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH
Reel/Frame 062857/0431 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2023
From: SCHROEDER, FRANK C.
To: BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH
Reel/Frame 062917/0357 →
Continuity (9)
Division 16685375 · Nov 15, 2019
Continuation 16251750 · Jan 18, 2019
Continuation 15833474 · Dec 6, 2017
Continuation 14237795
Provisional Application 61620343 · Apr 4, 2012
Provisional Application 61620348 · Apr 4, 2012
Provisional Application 61620331 · Apr 4, 2012
Provisional Application 61521295 · Aug 8, 2011
Related Publication 20230024046A1 · Jan 26, 2023
Cited By (1)
US 12,473,323